Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERTO M NIETO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1750430419
CMS profile
306412
Location
MANSFIELD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$18,631.38

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERTO M NIETO

NPI 1750430419 · CMS profile ID 306412

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

MANSFIELD, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750430419?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERTO M NIETO, NPI 1750430419, CMS profile ID 306412. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750430419?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROBERTO M NIETO, NPI 1750430419, CMS profile ID 306412. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750430419?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROBERTO M NIETO, NPI 1750430419, CMS profile ID 306412, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1750430419?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $18,631.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $6.5307/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012146987 CMS
EMD Serono, Inc. $48.4707/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032407291 CMS
EMD Serono, Inc. $26.2007/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032413113 CMS
Teva Pharmaceuticals USA, Inc. $25.3607/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056712633 CMS
EMD Serono, Inc. $3,273.0007/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032409233 CMS
Genentech USA, Inc. $24.7907/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040530505 CMS
Biogen, Inc. $23.9207/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012253057 CMS
BANNER LIFE SCIENCES, LLC $34.2907/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021112263 CMS
EMD Serono, Inc. $2,975.0006/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052753023 CMS
IDORSIA PHARMACEUTICALS US INC $20.0006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038250767 CMS
ABBVIE INC. $4.4206/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998014729 CMS
Teva Pharmaceuticals USA, Inc. $13.6806/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056712453 CMS
EMD Serono, Inc. $4,463.0006/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032406719 CMS
EMD Serono, Inc. $4,463.0006/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032406729 CMS
EMD Serono, Inc. $51.3006/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032468221 CMS
Neurocrine Biosciences, Inc. $30.0906/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052107873 CMS
ACADIA Pharmaceuticals Inc $24.2706/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053153245 CMS
ABBVIE INC. $17.5406/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998014727 CMS
EMD Serono, Inc. $356.4006/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032421485 CMS
ABBVIE INC. $4.1706/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998014725 CMS
Amneal Pharmaceuticals LLC $23.2206/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053520471 CMS
IDORSIA PHARMACEUTICALS US INC $23.5005/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038244253 CMS
Biogen, Inc. $8.9205/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012209577 CMS
Kyowa Kirin, Inc. $28.1805/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027020917 CMS
Horizon Therapeutics plc $15.1205/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987052515 CMS
Corium, LLC $29.6605/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978205865 CMS
EMD Serono, Inc. $394.4805/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032420945 CMS
ABBVIE INC. $16.1104/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998014723 CMS
Otsuka America Pharmaceutical, Inc. $16.4004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014636215 CMS
GENZYME CORPORATION $74.9904/13/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049732489 CMS
Novartis Pharmaceuticals Corporation $13.1604/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992915737 CMS
Harmony Biosciences LLC $14.2404/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013677399 CMS
UPSHER-SMITH LABORATORIES LLC $15.1304/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 994139307 CMS
EMD Serono, Inc. $373.7204/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032553216 CMS
Merck Sharp & Dohme LLC $20.6804/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048258113 CMS
Abbott Laboratories $22.7803/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019191455 CMS
Medtronic, Inc. $20.0303/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026323599 CMS
ABBVIE INC. $13.0203/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998014721 CMS
Biogen, Inc. $3.1703/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012216019 CMS
Biogen, Inc. $1.4303/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012224675 CMS
EMD Serono, Inc. $200.0003/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052754315 CMS
ABBVIE INC. $12.5803/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998014719 CMS
Amgen Inc. $16.3903/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020090809 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.8403/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055513767 CMS
Lilly USA, LLC $18.1402/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032288733 CMS
SK Life Science, Inc. $17.0802/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054709719 CMS
Biogen, Inc. $22.1902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012148133 CMS
UPSHER-SMITH LABORATORIES LLC $13.3702/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 994139831 CMS
Alexion Pharmaceuticals, Inc. $18.9402/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017006523 CMS
ABBVIE INC. $17.1301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998014717 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,831.48 271
PY2020 $46,593.92 237
PY2021 $44,327.22 269
PY2022 $34,237.07 203
PY2023 $18,631.38 108
PY2024 $3,068.08 172
PY2025 $25,254.19 227

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $33,938.50 25
PY2019 Principal investigator $44,133.02 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $1,132.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749126355
Principal investigator 1 Eisai Inc. $1,604.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127177
Principal investigator 1 Eisai Inc. $918.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127179
Principal investigator 1 Eisai Inc. $531.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127181
Principal investigator 1 Eisai Inc. $75.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127183
Principal investigator 1 Eisai Inc. $1,783.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127185
Principal investigator 1 Eisai Inc. $75.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127187
Principal investigator 1 Eisai Inc. $531.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127189
Principal investigator 1 Eisai Inc. $868.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128231
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128469
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128471
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128473
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128475
Principal investigator 1 Eisai Inc. $1,733.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749128477
Principal investigator 1 Eisai Inc. $9,173.70 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749129683
Principal investigator 1 Eisai Inc. $253.40 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130377
Principal investigator 1 Eisai Inc. $113.20 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130393
Principal investigator 1 Eisai Inc. $7.50 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130397
Principal investigator 1 Eisai Inc. $12.50 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130455
Principal investigator 1 Eisai Inc. $25.00 06/16/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749130483
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,250.80 03/11/2020 Non-covered Recipient Entity
NEUROLOGICAL ASSOCIATES OF ALRINGTON PA
LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY STARTED WITH FINGOLIMOD ONCE DAILY OR TREATED WITH ANOTHER APPROVED DISEASE MODIFYING THERAPY No dispute reported 06/30/2026 721493843
Principal investigator 1 Eisai Inc. $1,500.00 02/11/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127269
Principal investigator 1 Eisai Inc. $300.00 02/11/2020 Non-covered Recipient Entity
CCM CLINICAL RESEARCH GROUP
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749127271
Principal investigator 1 UCB SA $2,053.00 02/04/2020 Non-covered Recipient Entity
ARLINGTON GASTROENTEROLOGY ASSOCIATES, LLP
MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM No dispute reported 06/30/2026 746126279
Principal investigator 1 UCB SA $1,067.40 02/04/2020 Non-covered Recipient Entity
ARLINGTON GASTROENTEROLOGY ASSOCIATES, LLP
MULTICENTER 1-YEAR OBSERVATIONAL STUDY OF PATIENTS WHO ARE INITIATING BRIVARACETAM No dispute reported 06/30/2026 746128421